Patent ID: 6716871
Filing Date: 2004-04-06
Classification: A61K,A61P,C07D,Y02A

Abstract:
A method of treating a mammal suffering from obesity comprising administering to said mammal an effective amount of a pharmaceutical composition comprising (a) a compound of structural formula wherein R1 is selected from the group consisting of hydrogen, lower alkyl, bridged alkyl, aryl, cycloalkyl, C1-4alkylenearyl, C1-4alkyleneOaryl, C2-4alkylenearylOaryl, C1-4alkylene bridged alkyl, C1-4alkylenecycloalkyl, substituted or unsubstituted propargyl, substituted or unsubstituted allyl, and halocycloalkyl; R2 is selected from the group consisting of hydrogen, methyl, and halo-substituted methyl; R3 is selected from the group consisting of C(&boxH;O)OR7, C(&boxH;O)R7, NHC(&boxH;O)OR7, C1-3alkyleneC(&boxH;O)OR8, C1-3alkyleneC(&boxH;O)R8, C(&boxH;O)C(&boxH;O)OR8, C1-4alkyleneOR8, aryl, and C1-3alkylenearyl; R4 is selected from the group consisting of hydrogen, lower alkyl, haloalkyl, cycloalkyl, and aryl; R5 is selected from the group consisting of hydrogen, lower alkyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl, and aryl; R6 is selected from the group consisting of hydrogen, lower alkyl, and C(&boxH;O)R7; R7 is selected from the group consisting of lower alkyl, branched or unbranched, C1-4alkylenearyl, cycloalkyl, C1-4alkylenecycloalkyl, and aryl, each optionally substituted with one or more of OC(&boxH;O)R8, C(&boxH;O)OR8, OR8, or SR8; R8, same or different, is selected from the group consisting of hydrogen, lower alkyl, cycloalkyl, aryl, heteroaryl, C(&boxH;O)Oalkyl, C(&boxH;O)Oaryl, C(&boxH;O)alkyl, alkylSO2, haloalkylSO2, C(&boxH;O)C1-3alkylenearyl, C(&boxH;O)OC1-4alkylenearyl, C1-4alkylenearyl, and Het; R10 is selected from the group consisting of hydrogen, alkyl, haloalkyl, cycloalkyl, aryl, C(&boxH;O)alkyl, C(&boxH;O)cycloalkyl, C(&boxH;O)aryl, C(&boxH;O)Oalkyl, C(&boxH;O)Ocycloalkyl, C(&boxH;O)aryl, CH2OH, CH2Oalkyl, CHO, CN, NO2, and SO2R11; R11 is selected from the group consisting of alkyl, cycloalkyl, trifluoromethyl, aryl, aralkyl, and NR8R9; or a salt or solvate thereof; and (b) a pharmaceutically acceptable carrier.